I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...

Corvus Pharmaceuticals (CRVS) is in the process of evaluating the use of its interleukin-2-inducible T cell kinase [ITK] inhibitor for the treatment of patients with a wide variety of lymphoma types, ...

Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company also ...

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium ...

– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a ...

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...